Julie K. Jadlowsky

May 1, 2024 | jci.org | Pablo Tebas |Julie K. Jadlowsky |Pamela A. Shaw |Lifeng Tian

ErratumOpen Access | 10.1172/JCI181576 Published inVolume 134, Issue 9onMay 1, 2024J Clin Invest. 2024;134(9):e181576. https://doi.org/10.1172/JCI181576. © 2024 replicationThis work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Mar 13, 2024 | nature.com | Stephen J. Bagley |Meghan T. Logun |Julie K. Jadlowsky |Fang Chen |MacLean P. Nasrallah |Wei-Ting Hwang | +5 more

AbstractRecurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). The study’s primary endpoints were safety and determination of the maximum tolerated dose.